# A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine

> **NCT00542893** · PHASE1 · COMPLETED · sponsor: **Genta Incorporated**

## Conditions studied

- Advanced Melanoma

## Interventions

- **DRUG:** Genasense® (G3139, oblimersen sodium)
- **DRUG:** Genasense followed by DTIC; then DTIC alone
- **DRUG:** DTIC alone; then Genasense followed by DTIC

## Key facts

- **NCT ID:** NCT00542893
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** — (—)
- **Last updated:** 2012-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542893, "A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00542893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*